Monkeypox vaccine and research related stocks taking center stage (VRAX,GOVX,TNXP,APDN)

September 02, 2022 at 13:56 PM EDT

WH recently announced that its expanding monkeypox vaccination efforts. The infection seems to be slowed down in some major cities like New York and Chicago. However, cases seem to be popping in other parts of the country. Greenwood District 50 Schools revised its statement released Wednesday night to classify the incident as a "potential case of moneypox," after a request from the South Carolina Department of Health and Environmental Control. DHEC has not identified the individual. On July 29 New York State governor, Kathy Hochul, declared the monkeypox outbreak a state emergency. On August 2, president Joe Biden named two federal officials, Bob Fenton and Dr. Daskalakis to lead and accelerate the U.S. government's response against monkeypox.

Many of the world's leading healthcare providers such as Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), and Merck & Co., Inc. (NYSE: MRK) seem to still devote their research and development efforts to battle the COVID-19 pandemic instead of addressing the alarming monkeypox situation.

Let’s take a look at some of the biotech companies that seems to be ahead in the race to Monkeypox vaccine development.

Virax Biolabs Group Ltd (NASDAQ: VRAX) began listing its common shares on the Nasdaq Capital Market on July 21, 2022. VRAX claims itself to be an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases. Chairman of the Board and Chief Executive Officer, James Foster rang the Nasdaq Stock Market closing bell on Thursday, August 18, 2022. Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes.

GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and cancers. On August 3, GeoVax Labs, Inc. (NASDAQ: GOVX) reported that it has begun an animal study to evaluate a Phase 1 clinical trial for its MVA-VLP-MUC1 immunotherapy candidate. The company reported that its MVA-based vaccines, particularly the company's GEO-CM04S1, are effective against monkeypox. GeoVax Labs, Inc. (NASDAQ: GOVX) said that it is currently evaluating the GEO-CM04S1 and its effectiveness against monkeypox and said that it expects the vaccine to be able to treat both COVID-19 and monkeypox.

Applied DNA Sciences, Inc. (NASDAQ: APDN) develops and markets DNA-based technology solutions for use in nucleic acid-based vitro diagnostics and preclinical nucleic-acid-based drug development and manufacturing markets. The company is a leader in polymerase chain reaction technologies and on August 2, announced that it has initiated analytical validation of its PCR-based monkeypox virus test that is mapped onto the genetic signature of the monkeypox virus. As of August 5, Applied DNA Sciences, Inc. (NASDAQ: APDN) has surged 73.51% over the past six months.

On July 28, Tonix Pharmaceuticals Holdings Corp. (NASDAQ: TNXP) announced that it will be working with the Kenya Medical Research Institute to seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to commence in the first half of 2023.

It would be interesting to see how the market reacts to rising monkeypox cases around the world and USA. Signup at InvestorBrandMedia.com for more news and small cap stock alerts.

Disclaimer: InvestorBrandMedia is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available in this article is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall Investor Brand Media be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by Investor Brand Media ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. InvestorBrandMedia.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Investor Brand Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting InvestorBrandMedia.com/Disclaimer. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Country: United States
Website: https://investorbrandmedia.com/

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Monkeypox vaccine and research related stocks taking center stage (VRAX,GOVX,TNXP,APDN)

More News